cns-2022-0005 Suppl.pdf (96.56 kB)

Supplementary Tables 1 and 2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.

dataset

posted on 2022-05-16, 10:12 authored by John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O’Brien, Shiao-Pei Weathers, Nazanin K Majd, Rebecca A Harrison, Gregory N. Fuller, Jason T. Huse, James P. Long, Raymond Sawaya, Ganesh Rao, Tobey J. MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B. Heimberger

Supplementary Table 1.

Supplementary Table 2: PK Modeling Summary of WP1066 in Human Plasma

Funding

Support for this research was received from The Ben and Catherine Ivy Foundation and The University of Texas MD Anderson Moon Shot Program. Amy B Heimberger has licensed intellectual property to Celldex Therapeutics and DNAtrix. She serves on the advisory board of Caris Life Sciences, WCG Oncology, owns stock in Caris Life Sciences and has received research funding from Celularity Inc. and Codiak BioScience Inc. Moleculin has licensed WP1066 from MD Anderson Cancer Center that was created by Waldemar Priebe and provided study drug and reimbursement for PK analysis. Study supported by NIH grants: CA120813, NS120547, CA093459 and Cancer Prevention Research Institute of Texas (CPRIT) IIRA RP160482.

History

Usage metrics

Categories

Chemotherapy

Keywords

Glioblastoma Phase I STAT3 inhibitor toxicity

Licence

CC BY-NC-ND 4.0

Exports